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sociation between persistence with statins and risk of incident cardiac events. The
most persistent users (PDC  80%) had a hazard ratio of 0.62 (95% confidence
interval: 0.58-0.67) compared to non-persistent users (PDC 20%). Similar results
were found when analyses were limited to patients with more than 5 years of
follow up. An interaction analysis between persistence and other factors detected
a stronger risk reduction among diabetic males. CONCLUSIONS: This large and
unselected community-based study supports the results of several randomized
controlled trials regarding the beneficial effect of persistent statin therapy against
cardiac events among primary prevention patients.
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OBJECTIVES: Healthcare Effectiveness Data and Information Set (HEDIS) defines
controlled hypertension as systolic/diastolic BP (SBP/DBP) 130/80 mm Hg for pa-
tients with essential hypertension and diabetes. We estimated the percentage of
diabetes patients with uncontrolled essential hypertension who would reach SBP
goals with the angiotensin II receptor blockers (ARBs) azilsartan medoxomil, val-
sartan, and olmesartan medoxomil. METHODS: A Monte Carlo simulation model
was created to estimate the number of patients with hypertension (SBP 130 mm
Hg) and diabetes who would achieve SBP goal when treated with azilsartan med-
oxomil, valsartan, or olmesartan medoxomil for 12 months. A cohort of 100,000
hypothetical diabetes patients with uncontrolled hypertension was created from
NHANES 1999–2006 and assigned a baseline SBP. Follow-up SBPswere generated by
randomly sampling from themean and SD of the percentage change from baseline
to final visit in sitting office SBPs by using data from the diabetes subpopulation
from the azilsartanmedoxomil clinical trial program.MeanSD relative changes in
SBP were 10.36%10.41, 4.58%11.04, 5.16%11.82% (F-test P.001) for azil-
sartan medoxomil, valsartan,and olmesartan medoxomil, using the pooled effica-
cies across all dosages, respectively. We assessed goal attainment assuming that
adherence was alternatively perfect and that 48% of patients receiving any ARB
would discontinue treatment. RESULTS: Patient characteristics based on NHANES
data were meanSD age 5613 years, 56% male, 23% with prior cardiovascular
disease, baseline SBP 15119mmHg.We estimated that 41.0%of patients receiving
azilsartanmedoxomil would achieve SBP goal vs. 26.8% for valsartan and 28.8% for
olmesartan medoxomil, assuming perfect adherence; accounting for nonadher-
ence, 21.2%, 13.9%, and 14.8% of patients would reach SBP goals, respectively.
CONCLUSIONS:Our findings suggest thatmore diabetes patients treatedwith azil-
sartan medoxomil than with valsartan or olmesartan medoxomil are expected to
reach SBP goal. Further analysis should address whether these differences in SBP
translate into better HEDIS quality scores.
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OBJECTIVES: Low molecular weight heparins (LWMH) are indicated in unstable
angina and non-Q-wave myocardial infacrtion. Even though both agents have
demonstrated safety and at least comparable efficacy to unfractionated heparin
(UH), there have been no head to head trials to assess comparative effectiveness.
Meta analytic techniques were used to perform an indirect statistical comparison
between dalteparin and enoxaparin in patients with unstable coronary artery dis-
ease (UCAD). METHODS: A literature search was conducted from January 1980 to
November 2009 for randomized controlled trials evaluating dalteparin or enoxa-
parin for the prevention of myocardial infarctions (MI) and death in UCAD. Binary
outcomes (e.g. MIs, death) for the LMWH relative to UH were statistically pooled
using a fixed effectsmodel. Using UH as the common control, an indirect statistical
comparison between dalteparin and enoxaparinwas performedusingmeta regres-
sion analysis with active drug (dalteparin or enoxaparin) as the primary indepen-
dent variable. RESULTS: Six UH controlled enoxaparin (n4) and dalteparin (n2)
trials met the inclusion criteria. The meta analysis of all trial data showed that
patients treated with enoxaparin or dalteparin had an 11% relative risk reduction
for MI compared to UH (RR  0.89, p  0.009). This benefit was achieved without a
significant increase in the risk for major bleeding (RR 0.98, p 0.85), thrombocy-
topenia (RR  1.14, p  0.35) or death (RR  0.95, p  0.68). The indirect statistical
comparison was unable to find significant differences between enoxaparin and
dalteparin in terms of MI (p0.67), major bleeds (p0.79), thrombocytopenia
(p0.23) or death (p0.10). CONCLUSIONS:Our findings suggest comparable safety
and efficacy between dalteparin and enoxaparin when used to prevent MI and
death in patients with UCAD. Therefore, treatment decisions should be based on
other considerations, such as patient or physician preference, ease of administra-
tion and cost.
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OBJECTIVES: No major clinical trial has compared rosuvastatin with atorvastatin
in preventing major adverse cardiovascular events (MACE). This study estimated
the effectiveness of rosuvastatin 20mg (R20) versus atorvastatin 40mg (A40) and
80mg (A80) in preventing MACE in several higher cardiovascular risk patient pop-
ulations using simulation. METHODS: The extensively validated and published
Archimedes model was used to simulate head-to-head clinical trials in several
populations [10-year Framingham risk score (FRS) 5%, FRS20%, EURO-SCORE
5, Diabetes, secondary prevention, and Acute Coronary Syndrome (ACS)] to esti-
mate the occurrence of MACE (comprising MI, stroke, and cardiovascular death)
over time. Patients (ages 45–70) based on the National Health and Nutrition Exam-
ination Survey were enrolled in trial simulations. Treatments were modeled and
validated using biomarker and outcomes data from published trials. RESULTS: The
number of patients in each arm ranged from 3,060 to 55,000, depending on the trial
population. R20 reduced MACE more than A40 or A80 in all scenarios, with higher
risk subgroups showing greater absolute benefit. In individual trial simulations, the
5 year relative risk (RR) of MACE for R20 versus A40 ranged from 0.90 to 0.92.
Similarly, the 5 year RR ofMACE for R20 versus A80 ranged from0.93 to 0.95. Similar
estimates were observed at 10 and 20 years. The 5-year number needed to treat
(NNT) to prevent one MACE event with R20 vs. A40 and A80 decreased consistently
with increasing baseline cardiovascular risk (for R20 vs. A40, NNT of 268 for FRS
5% and 55 for ACS). CONCLUSIONS: Themodel estimated that R20 lowers the risk
ofMACEmore thanA40 or A80.While simulationmodels cannot replace controlled
clinical trials, this study bridges gaps in the evidence and helps identify cohorts
that would benefit most from treatment with rosuvastatin rather than atorvasta-
tin.
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OBJECTIVES: Length of hospital stay (LOS) is a major cost component of hospital
budgets. Accurate prediction of LOS has become increasingly important for health
care systems, and reducing the LOS has the potential for large savings in the public
hospital system. This study aimed to assess the factors associated with prolonged
LOS of acute ischemic stroke taking into consideration demographic, risk factors,
and clinical signs that can be assessed at the time of admission. Particular atten-
tion is paid on the impact of previous medication use on LOS.METHODS: A retro-
spective cohort study of all acute ischemic stroke survivors attending a hospital in
Malaysia fromMay 1, 2008 to December 31, 2008. Long hospital stay was defined as
a stay greater than or equal to the median of LOS. Data included demographic
information, clinical information, risk factors, and previous medication use. SPSS
version 15was used for data analysis. RESULTS:Overall, 363 patients were studied.
The median (interquartile range) of LOS was 69 (45-111) hours. The independent
factors associatedwith prolonged LOSwere a history of atrial fibrillation (P 0.011),
patients with moderate and severe Glasgow Coma Scale (P  0.001), patients with
higher body temperature (P  0.015), patients with higher fasting or random blood
glucose (P  0.004), and patients without previous use of angiotensin converting
enzyme inhibitor medication (P  0.027). CONCLUSIONS: This study provided sci-
entific data for the factors that could hamper the discharge, particularly before
clinicians can evaluate the most effective, efficient, and acceptable methods of
managing patients with acute ischemic stroke. Moreover, these variables are po-
tentially preventable or treatable at admission time and would be ideal targets to
reduce the burden of illness and healthcare costs of ischemic stroke.
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OBJECTIVES: Acute ischemic stroke (AIS) is a major public health concern and
among the leading causes of death and disability in western societies. The man-
agement of AIS and its long term evolution in the USA and Canada was assessed
through a literature search.METHODS: Medline was searched for the time period
1999-2010 to identify stroke cohorts and registries containing relevant data on AIS
management and/or long term evolution. Subsequently, a ranking process was
used to identify and select the most relevant references. RESULTS: A total of 680
referenceswere retrieved (581USA and 99 Canada). Publications frommore than 80
distinct cohorts/registries/databases were analyzed and a final selection led to the
identification of 43 publications for the USA and 25 for Canada. IS proportion
among all strokes ranged from 43%-90% in hospital cohorts. 24%-33% of all stroke
patients arrived at the hospital within 3 hour of symptom onset and rt-PA treat-
ment was received in 1.1%-14% of all AIS patients. The majority of patients, i.e.
82%-100% underwent a CT/MRI scanning. In general, hospital setting and care
characteristics were poorly documented and relatively few quality indicators of
stroke management were targeted. For long term evolution outcomes, mortality
was well documented (5%-17% 1 month, 17%-35% 3 months, 30%-37% 3 years,
37%-54% 5 years). AIS recurrence and cardiac events were described in few, mainly
USA, studies. There was a lack of data on disability (modified Rankin Scale) evolu-
tion after 3 months and studies on depression were scarce. CONCLUSIONS: Hos-
pital setting, characteristics of care, and long term evolution of disability are poorly
documented in American and Canadian registries. New cohort and registry studies
should specifically aim to generate real life data on ischemic stroke care that influ-
ence short and long-term clinical and associated economic outcomes.
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